Sanofi's Mixed Itepekimab Results Make Amlitelimab Trial More Important -- Market Talk

Dow Jones

Jun 02, 2025

1129 GMT - Sanofi's mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 02, 2025 07:29 ET (11:29 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540677857"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540677857\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540677857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540677857","market":"fut","top_or_hot":-1,"title":"Sanofi's Mixed Itepekimab Results Make Amlitelimab Trial More Important -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1129 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2025 07:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Mixed Itepekimab Results Make Amlitelimab Trial More Important -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Mixed Itepekimab Results Make Amlitelimab Trial More Important -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-02 19:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1129 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2025 07:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540677857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540677857","pubTimestamp":1748863740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1129 GMT - Sanofi's mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4007":"制药","SNY":"赛诺菲安万特","BK4588":"碎股"},"translate_title":"赛诺菲的Itepekimab结果好坏参半，Amlitelimab试验变得更加重要——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9},"content_text":"1129 GMT - Sanofi's mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2025 07:29 ET (11:29 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}